Fortrea Holdings (FTRE)

Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.

The Fortrea Holdings Inc. Common Stock (FTRE) stock price today is $10.72, reflecting a -0.79% move since the market opened. The company’s market capitalization stands at $990.53M, with a daily trading volume of $2.61M shares. For investors tracking price trends, Fortrea Holdings Inc. Common Stock stock has ranged between $10.12 and $11.09 today. The previous closing price was $10.81.

Ready to get started? Follow the steps below, or read our guide on how to buy Fortrea Holdings stock on Kraken starting from $10.